Schizotypal personality disorder

disease

On this page

Summary

Schizotypal personality disorder (MONDO:0001087) is a disease and 11 clinical trials. Top therapeutic interventions include guanfacine, pergolide, and risperidone. A subtype of personality disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	schizotypal personality disorder
Mondo ID	MONDO:0001087
MeSH	D012569
DOID	DOID:10646
ICD-10-CM	F21
ICD-11	18178000
NCIT	C92632
SNOMED CT	31027006
UMLS	C1443045
MedGen	1826899
Is cancer (heuristic)	no

Disease family

This is a subtype of personality disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › personality disorder › schizotypal personality disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Guanfacine.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE2	3
PHASE4	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00353379	PHASE4	TERMINATED	Pharmacology of Cognition in Schizotypal Personality Disorder
NCT01466205	PHASE2	UNKNOWN	Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder
NCT02507206	PHASE2	COMPLETED	A D1 Agonist For Working Memory
NCT02524899	PHASE2	COMPLETED	CRT-Guanfacine for SPD
NCT02535156	PHASE1/PHASE2	COMPLETED	Schizotypal Personality Disorder Risperidone
NCT02149823	PHASE1	TERMINATED	Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
NCT00158028	Not specified	COMPLETED	Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder
NCT00252044	Not specified	UNKNOWN	Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
NCT02800681	Not specified	COMPLETED	Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult Sample
NCT04764708	Not specified	COMPLETED	Compassion and Metacognition in Schizotypal Personality
NCT05710926	Not specified	UNKNOWN	Evolutionary Systems Therapy for Schizotypy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GUANFACINE	4	6
PERGOLIDE	4	3
RISPERIDONE	4	2
DIHYDREXIDINE	2	1
CHEMBL1290665	0	1

Drugs: Guanfacine, Pergolide, Risperidone